Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Demartinis

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Drug Investigation|February 26, 2018
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's DiseaseRachel Gurrell, Sridhar Duvvuri, Pengling Sun, et al.
Lancet (London, England)|December 20, 2005
Case report: Marathon runner with severe autonomic failureEmily M Garland, Satish R Raj, Nicholas Demartinis, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute SchizophreniaDavid P Walling, Anindita Banerjee, Vikas Dawra, et al.
Annals of Clinical and Translational Neurology|May 21, 2021
Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxiaHao Wang, Jonathan Norton, Lin Xu, et al.
Journal of Clinical Psychopharmacology|June 18, 2019
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of SchizophreniaNicholas DeMartinis, Rene N Lopez, Eve H Pickering, et al.
International Journal of Offender Therapy and Comparative Criminology|September 26, 2007
Psychiatric use and utility of divalproex sodium in Connecticut prisonsJayesh Kamath, Humberto D Temporini, Susan Quarti, et al.
Journal of Psychopharmacology (Oxford, England)|July 3, 2019
A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophreniaEstibaliz Arce, Rita Balice-Gordon, Sridhar Duvvuri, et al.
Schizophrenia Research|June 29, 2024
INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophreniaVenkatesha Murthy, Elizabeth Hanson, Nicholas DeMartinis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 23, 2016
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430Mika Naganawa, Rikki N Waterhouse, Nabeel Nabulsi, et al.
The International Journal of Neuropsychopharmacology|February 15, 2020
A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory CapacityRita Balice-Gordon, Garry D Honey, Christopher Chatham, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Drug Investigation|February 26, 2018
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's DiseaseRachel Gurrell, Sridhar Duvvuri, Pengling Sun, et al.
Lancet (London, England)|December 20, 2005
Case report: Marathon runner with severe autonomic failureEmily M Garland, Satish R Raj, Nicholas Demartinis, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute SchizophreniaDavid P Walling, Anindita Banerjee, Vikas Dawra, et al.
Annals of Clinical and Translational Neurology|May 21, 2021
Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxiaHao Wang, Jonathan Norton, Lin Xu, et al.
Journal of Clinical Psychopharmacology|June 18, 2019
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of SchizophreniaNicholas DeMartinis, Rene N Lopez, Eve H Pickering, et al.
International Journal of Offender Therapy and Comparative Criminology|September 26, 2007
Psychiatric use and utility of divalproex sodium in Connecticut prisonsJayesh Kamath, Humberto D Temporini, Susan Quarti, et al.
Journal of Psychopharmacology (Oxford, England)|July 3, 2019
A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophreniaEstibaliz Arce, Rita Balice-Gordon, Sridhar Duvvuri, et al.
Schizophrenia Research|June 29, 2024
INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophreniaVenkatesha Murthy, Elizabeth Hanson, Nicholas DeMartinis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 23, 2016
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430Mika Naganawa, Rikki N Waterhouse, Nabeel Nabulsi, et al.
The International Journal of Neuropsychopharmacology|February 15, 2020
A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory CapacityRita Balice-Gordon, Garry D Honey, Christopher Chatham, et al.
Pageof 1